Acute monocytic leukemia-associated antigen MLAA-34 epitope polypeptide, and vaccine and pharmaceutical application of acute monocytic leukemia-associated antigen MLAA-34 epitope polypeptide

Abstract

The invention discloses an acute monocytic leukemia-associated antigen MLAA-34 epitope polypeptide and an application of the acute monocytic leukemia-associated antigen MLAA-34 epitope polypeptide, and belongs to the technical field of biology. The acute monocytic leukemia-associated antigen MLAA-34 epitope polypeptide disclosed by the invention can induce specific CTL, and simultaneously can express tumor cells of MLAA-34 and HLA-A*0201, and T2 cells of loaded peptide in vitro to generate the determined specific killing effect; the epitope polypeptide CP701 is applied to preparation of a polypeptide vaccine aiming at acute monocytic leukemia; and the polypeptide vaccine composed of an MLAA-34 epitope peptide CP701 (236ILDRHNFAI244), a T auxiliary epitope and an incomplete Freund adjuvant can inhibit hu-PBL-SCID amplification of tumors in mice loading human monocytic leukemia cells THP-1, prolongs the survival life, and can induce the specific CTL killing activity and NK cytotoxic activity in vivo.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to an acute monocytic leukemia-associated antigen MLAA-34 epitope polypeptide and its vaccine and pharmaceutical application. Background technique [0002] Acute myeloid leukemia (AML) has a poor prognosis, especially those with adverse chromosomal or molecular abnormalities, mainly due to the high relapse rate after chemotherapy-induced remission. The eradication of minimal residual disease (MRD) after remission remains a huge challenge. Allogeneic hematopoietic stem cell transplantation (hematopoietic stem cell transplantation, HSCT) shows effective anti-leukemia effect, but because of the difficulty of matching, high cost, and more importantly, some life-threatening complications, such as graft-versus-host disease ( graft versus host disease, GVHD), only suitable for a small number of young and suitable patients. Therefore, there is an urgent need to develop new therape...

AI Technical Summary

Problems solved by technology

The biggest weakness of a single polypeptide vaccine is its poor immunogenicity, the polypeptide is easily degraded by peptidases in the body, and the induced CTL is not easy to break through the threshold required for tumor regression

For example, although the WT1 epitope peptide vaccine has achieved initial success in clinical trials, current researchers often use peptides with a single CTL epitope, which are small in molecular weight and easily degraded by proteolytic enzymes, so they can only stimulate low-level immune responses. Combining multiple CTL epitopes, increasing Th epitopes, using immune adjuvants, constructing multi-epitope peptides and fusion peptides can improve the immunogenicity of polypeptides

Images